Skip to main content
Clinical Trials/CTRI/2018/04/013063
CTRI/2018/04/013063
Completed
Phase 3

Study of Efficacy,Safety and Tolerability of Ayurvedic Formulation in participants with Diabetic Kidney Disease

Dr Aparna Sathe0 sites99 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: null- k/c/o/ Diabetic Kidney Disease. 3months k/c/o Type 2 DM at least since 6 months.Health Condition 2: E112- Type 2 diabetes mellitus with kidney complicationsHealth Condition 3: E112- Type 2 diabetes mellitus with kidney complications
Sponsor
Dr Aparna Sathe
Enrollment
99
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 2, 2020
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Aparna Sathe

Eligibility Criteria

Inclusion Criteria

  • 1\. Adult ( \>18 yrs) either gender with prior diagnosis of DKD.
  • 2\. Known case of Type 2 DM diagnosed at least since 6 months.
  • 3\. CKD stage 3
  • 3 a : e GFR (EPI) 45 to \< 60
  • 3 b : e GFR (EPI) 30 to \< 45
  • 4\. Participants on stable and acceptable dose of ACE inhibitors or ARB (angiotensin II receptor blockers)

Exclusion Criteria

  • 1\)Type I DM
  • 2\)Lack of clinical evidence or suspicion of renal diagnosis other than DKD
  • 3\)UACR \> 5000mg/g on any major measurement during screening.
  • 4\)Uncontrolled Diabetes (HB1Ac \> 8%)
  • 5\)ESRD receiving dialysis or Anticipated progression to ESRD within treatmentperiod.
  • 6\)Status postrenal transplant.
  • 7\)Unstable CVD
  • 8\)Other concomitant disease that could impair patients safety or ability to participate in study.
  • 9\)Known case of Immunocompromised patients or subjects on immunorupressive drugs.
  • 10\)Pregnant and lactating females.

Outcomes

Primary Outcomes

Not specified

Similar Trials